|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Vumerity
|
|
gptkbp:activities
|
anti-inflammatory
|
|
gptkbp:appointed_by
|
oral capsule
|
|
gptkbp:approves
|
gptkb:2020
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Vumerity
|
|
gptkbp:category
|
disease-modifying therapies
|
|
gptkbp:class
|
immunomodulators
|
|
gptkbp:clinical_trial
|
Phase 3
ongoing studies
chronic treatment
|
|
gptkbp:contraindication
|
hypersensitivity to diroximel fumarate
|
|
gptkbp:developed_by
|
gptkb:Biogen
|
|
gptkbp:dosage_form
|
gptkb:beer
|
|
gptkbp:duration
|
long-term therapy
|
|
gptkbp:education
|
importance of adherence
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
oral medication
delayed-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
diroximel fumarate
|
|
gptkbp:indication
|
gptkb:relapsing_forms_of_multiple_sclerosis
|
|
gptkbp:ingredients
|
gptkb:diroximel_fumarate
C12 H14 N2 O4
|
|
gptkbp:interacts_with
|
other immunosuppressants
may interact with anticoagulants
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
liver function tests
|
|
gptkbp:is_used_for
|
gptkb:psychologist
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
blister packs
|
|
gptkbp:pharmacokinetics
|
modulates immune response
absorbed in gastrointestinal tract
|
|
gptkbp:population
|
adults
|
|
gptkbp:provides_information_on
|
MS treatment guidelines
|
|
gptkbp:related_to
|
fumaric acid esters
|
|
gptkbp:research
|
clinical efficacy studies
|
|
gptkbp:research_focus
|
neurological disorders
|
|
gptkbp:safety_features
|
generally well tolerated
monitor for liver toxicity
|
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
diarrhea
flushing
elevated liver enzymes
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
1202560-51-6
|
|
gptkbp:type_of_care
|
important for efficacy
|